BioSpace News Archive

Larimar Therapeutics, Inc. announced that it has received meeting minutes from the U.S. Food and Drug Administration following a recent Type C Meeting with the Agency and reported its second quarter 2022 operating and financial results.

Ventyx Biosciences, Inc. announced that it will report topline results from the Phase 1 trial of its selective, allosteric TYK2 inhibitor VTX958 as well as financial results for the second quarter ended June 30, 2022, after market close on August 15, 2022.

Mustang Bio, Inc. announced financial results and recent corporate highlights for the second quarter ended June 30, 2022.

Science 37 Holdings, Inc., the Agile Clinical Trial Operating System™, reported its financial results for the quarter ended June 30, 2022.

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal platform delivery technology, reported financial results for the second quarter ended June 30, 2022, along with a corporate update.

The Menarini Group and Stemline Therapeutics, a wholly-owned subsidiary of Menarini Group, announced that the U.S. Food and Drug Administration has accepted the Company’s New Drug Application for elacestrant, an investigational selective estrogen receptor degrader, for patients with ER+/HER2- advanced or metastatic breast cancer.

argenx (Euronext & Nasdaq: ARGX), today announced that the European Commission (EC) has granted marketing authorization for VYVGART™ (efgartigimod alfa-fcab) as an add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

Passage Bio, Inc. (Nasdaq: PASG), today announced that the first patient has been dosed in the global Phase 1/2 upliFT-D clinical trial evaluating PBFT02, an adeno-associated virus (AAV)-delivery gene therapy for the treatment of patients with frontotemporal dementia (FTD) with granulin (GRN) mutations.

Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and year-to-date fiscal 2022 ended June 30, 2022, with strong sales and continued positive net earnings, plus ongoing progress upon its strategic goal of increasing its capacity for medical devices production to thereby continue growing sales, margins, and earnings.

Acasti Pharma Inc., a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, announced financial and operational results for the first quarter ended June 30, 2022.